Effects of Vitamin D Supplementation in Obesity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01037140|
Recruitment Status : Completed
First Posted : December 21, 2009
Last Update Posted : August 2, 2012
Obesity is an increasing health problem with numerous metabolic complications. Vitamin D deficiency is common in obesity, and in epidemiological studies vitamin D deficiency has been linked to metabolic complications, such as type 2 diabetes, insulin resistance and cardiovascular disease, as well as myopathy, osteoporosis and depression. In obesity, a low grade inflammation is present in the fat tissue, thereby releasing inflammatory molecules to the blood stream. In cell line studies as well as small clinical studies vitamin D has been shown to have the ability to reduce inflammation and cell growth.
In the present study the investigators wish to investigate the effect of vitamin D on fat-, muscle and bone metabolism. 30 healthy obese subjects will be treated with cholecalciferol 175 micrograms daily for 6 months and will be compared with 30 healthy obese subjects treated with placebo.
The investigators hypothesize that restoring vitamin D levels in vitamin D deficient obese subject will reduce inflammation and thereby reduce obesity-related complications.
The effect will be evaluated as follows:
- Levels of circulating inflammatory markers will be examined in blood samples collected prior to and after treatment.
- Effects on fat- and muscle metabolism will be evaluated in fat- and muscle samples taken before and after treatment.
- Effects on fat distribution will be evaluated by MRI scan before and after treatment.
- Effects on insulin sensitivity will be evaluated by hyperinsulinaemic euglycaemic clamp performed on a subgroup of subjects with impaired fasting glucose.
- Effects on bone marrow density will be evaluated by DEXA scans before and after treatment.
- Effects on quality of life and depression score will be evaluated by questionnaires used before and after treatment.
|Condition or disease||Intervention/treatment||Phase|
|Vitamin D Deficiency Obesity||Drug: Cholecalciferol Drug: placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||55 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effects of Vitamin D Supplementation in Vitamin D Deficient Obese Subject.|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||December 2011|
|Actual Study Completion Date :||July 2012|
|Active Comparator: cholecalciferol||
oral cholecalciferol tablets of 175 micrograms daily for 6 months
Other Name: vitamin D
|Placebo Comparator: placebo||
oral placebo tablets similar to active comparator
- Effect on circulating inflammatory markers [ Time Frame: 6 months ]
- change in fat distribution [ Time Frame: 6 months ]
- change in insulin sensitivity [ Time Frame: 6 months ]
- change in bone mineral density [ Time Frame: 6 months ]
- change in quality of life [ Time Frame: 6 months ]
- change in depression score [ Time Frame: 6 months ]
- change in muscle function [ Time Frame: 6 months ]
- change in fat- and muscle metabolism [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01037140
|Dept. of Endocrinology and Metabolism, Aarhus University Hospital|
|Principal Investigator:||Louise Wamberg, Dr.||Aarhus University Hospital|